Abstract. Chemotherapy-induced peripheral neuropathic pain (CIPNP) is a serious, undesirable effect of cancer treatment which is particularly difficult to prevent. Berberine and its derivatives have been reported to display robust antioxidant and analgesic effects in rat models of diabetic neuropathic pain and peripheral nerve injury. However, the analgesic role of berberine on oxaliplatin-induced CIPNP remains unknown. The present study aimed to explore the analgesic effect of berberine on CIPNP. Sprague Dawley rats were used to create the CIPNP animal model by oxaliplatin administration. Behavioral tests were performed by von Frey test, acetone drop test, hot plate test, and motor coordination. The protein expression levels of NF-κB p65 and phosphorylated p65 in dorsal root ganglions (DGRs) were detected by western blot analysis. Finally, TNF-α and IL-6 levels in DRGs were measured using specific ELISA kits. The results from the behavioral analysis demonstrated that a single injection of berberine ameliorated the mechanical and cold allodynia and thermal hyperalgesia in the model rats in a dose-dependent manner. Cumulative administration of berberine prevented the mechanical and cold allodynia and thermal hyperalgesia in the development of CIPNP induced by oxaliplatin. This prophylactic effect of berberine was associated with reduced phosphorylation of p65 and with decreased levels of pro-inflammatory cytokines IL-6 and TNF-α. The present study indicated that berberine may have a role in preventing the development of CIPNP and may serve as a therapeutic compound for the treatment of CIPNP.

Introduction

Chemotherapeutic drugs, such as taxanes, vinca alkaloids, platinum analogs, topoisomerase inhibitors and proteasome inhibitors, can cause a series of adverse reactions. The most common and serious side-effect is chemotherapy-induced peripheral neuropathic pain (CIPNP) (1,2), which negatively affects patient quality of life, rendering it a major constraint for therapeutic drug dosage. Oxaliplatin is a platinum derivative that is widely used in first-line colorectal cancer therapy (3). Oxaliplatin can result in acute and chronic distal sensory neuropathy; the former is characterized as acral paresthesia triggered by cold temperatures and the latter is induced by accumulative oxaliplatin (4). Oxaliplatin-induced CIPNP complicates clinical treatment because there is a lack of effective analgesics, therefore, the treatment process may be accompanied by unacceptable side effects (5). There are currently no effective ways to treat or prevent oxaliplatin-induced CIPNP (6), necessitating the development of novel solutions.

Nuclear factor-κB (NF-κB) has a substantial role in regulating inflammation and immune responses (7) and is involved in the nervous system's synaptic plasticity, memory formation, learning, neurotransmission and neuroprotection (8,9). When the NF-κB signaling pathway is activated, NF-κB p65 can bind to the promoters of target genes and enhance their expression (10). Previous research has indicated that NF-κB activation is associated with the pathological pain caused by nerve injury or inflammation (11,12). Recent research has also reported NF-κB to be involved in CIPNP (13) and the establishment and maintenance of acute and chronic pain caused...
by neuroinflammation or nerve injury (14,15). Furthermore, NF-κB activation was demonstrated to regulate the levels of pro-inflammatory cytokines, including IL-6 and TNF-α, in a neuropathic pain model (16). However, it remains unclear whether oxaliplatin-induced CIPNP is associated with NF-κB pathway activation in dorsal root gangliaons (DRGs).

Natural plant products have been shown to effectively treat complex chronic comorbidities (17-19). Berberine, one of the tested compounds, is an isoquinoline alkaloid reportedly purified from herbs and featuring multiple pharmacological effects. Its antimicrobial and antisecretry properties have been used as a treatment to diarrhea and gastroenteritis (20,21). Berberine and its derivatives have also been shown to exhibit potent anti-inflammatory and anticancer properties (22). Additionally, berberine has alleviated allodynia and demonstrated antioxidative effects in models of diabetic neuropathy (23) and peripheral nerve injuries (24). However, there are no relevant reports on berberine's analgesic function on oxaliplatin-induced CIPNP; that is, no research has revealed berberine having a role as an adjuvant during chemotherapy.

The present study explored the effects of single injections and repeated doses of berberine on the induction and prevention of oxaliplatin-induced CIPNP, respectively. To investigate its underlying mechanism, the effects of berberine on oxaliplatin-induced modulation of NF-κB signaling and of pro-inflammatory cytokine secretion were also tested.

Materials and methods

**Animals.** Sprague Dawley rats (n=88, male, 200-220 g; Laboratory Animal Center of Huazhong University of Science and Technology, Wuhan, China) were housed in a room with 22-24°C and 12-h light/dark cycle (7:00 am to 7:00 pm). Food and water were freely available. All procedures complied strictly with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of Huazhong University of Science and Technology (Wuhan, China).

**Drug administration and experimental design.** Oxaliplatin (Dalian Meilun Biology Technology Co., Ltd.) was dissolved in saline. The rats were injected intraperitoneally (i.p.) with 2.5 mg/kg oxaliplatin for 4 consecutive days, after which a final dose of 10 mg/kg was administered to induce peripheral neuropathic pain. Berberine was used both as a treatment in pre-established oxaliplatin-induced CIPNP and as a prevention during the CIPNP induction process.

Berberine chloride was obtained from Shanghai Shifeng Biotechnology, Ltd. Berberine was dissolved in dimethyl sulfoxide (DMSO) at concentrations of 50, 100 and 200 mg/ml, and diluted in saline (0.9%) for injection. All solutions were filtered using a 0.22-µm membrane filter (Pall Life Sciences) prior to injection. To evaluate the effect of berberine as a treatment in pre-established oxaliplatin-induced CIPNP, a single dose of berberine (5, 10 or 20 mg/kg) was administered i.p. 21 days after the first oxaliplatin injection, according to a previous report (23). Von Frey, acetone drop and hot plate tests were performed 60 min after the injection of berberine. To evaluate the effect of berberine on the prevention of oxaliplatin-induced CIPNP, animals were injected i.p. with berberine or saline every 24 h for 21 consecutive days after the final injection with oxaliplatin. Animals were randomly divided into four groups (n=8): vehicle + saline group, oxaliplatin + saline group, oxaliplatin + berberine (10 mg/kg) group and oxaliplatin + berberine (20 mg/kg) group. Then, tissue samples were collected 24 h after the end of final behavioral tests. All behavioral tests were conducted at 10:00 am of each experiment day by researchers who were blinded to the animal groups.

**Mechanical allodynia (von Frey test).** Mechanical allodynia was evaluated by von Frey test. The rats were placed in a plastic chamber (20x17x13 cm) without bottom and with several compartments, and all of them were placed on a 40-cm high wire mesh shelf. At 15 min before the test, the rats were placed in the test box to adapt to the environment. An electronic von Frey instrument (IITC Life Science Inc.) was used to examine the rats’ behaviors. The withdrawal threshold was reflected by applying 0-50 g of pressure (with an accuracy of 0.2 g). Below the wire mesh floor, a punctuate stimulus was transmitted through the tip of the von Frey fiber to the middle part of each rat's hind paw for 2 sec. Then the von Frey instrument automatically reads the withdrawal threshold. The rat's sensitivity threshold is considered as the minimum pressure required to make the hind paw produce robust and immediate withdrawal reflex. Movement-related autonomous motions are not considered as withdrawal responses. The stimulus was given to the hind paw every 5 min. The measurement was repeated three times, and the average of three measurements was recorded as the final result.

**Cold allodynia (acetone drop test).** According to previous reports (25), cold allodynia was measured by acetone drop tests. In brief, rats were individually placed in plastic chambers which were put on a wire mesh shelf. Then a flat needle of a syringe was used to aspirate some acetone and one drop was gently dropped on the surface of the rat's hind paw. The time of withdrawal/licking reaction was recorded within 40 sec. Acetone was dropped every 10 min during the measurement, and the average of the responses was calculated in each measurement.

**Thermal hyperalgesia (hot-plate test).** Thermal hyperalgesia was evaluated by a hot plate analgesic instrument (Bioseb). Rats were placed individually on a hot plate with a constant temperature of 53±1°C. An electronic timer was used to record the time required for reactions such as jumping or hind paw-licking. To prevent scalding of rat paws, the maximum heating time was set as 30 sec. Three repeat measurements were obtained for each rat, with an interval between each measurement of >10 min, then the average value of each measurement was calculated as the final result. Normal foot-lifting motions were not counted. The researcher performing the behavioral testing was blind to the grouping and administration of rats.

**Bodyweight and motor coordination.** All rats were weighed weekly on days 0, 7, 14 and 21. A rotarod apparatus (Shanghai Mobile Data Center) was used to evaluate the motor coordination of rats. The rats were trained for 10 min with 10, 20 and 30 rpm on the equipment for 3 consecutive days to let them
familiarize with the device, until they could persist for 60 sec with not falling. During the test, the rats were placed with a variable mode of 4-40 rpm and allowed to run until they fell or reached the 5-min cut-off time. The time from the beginning of the test to the fall was recorded.

**Tissue collection.** After completing the behavioral tests, rats were anesthetized with pentobarbital sodium (50 mg/kg, i.p.; Sigma-Aldrich; Merck KGaA) and sacrificed by cervical dislocation. DRGs from lumbar (L) 4-L6 were dissected and quick-frozen in liquid nitrogen, then stored in -80°C until further experiments.

**Protein preparation and western blot analysis.** Samples were homogenized in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, pH 7.4) to extract the protein. The protein preparations were stored at -80°C. The protein concentration in each sample was determined using a BCA assay. Equal amounts of protein (25 µg) were separated on 10% Tris-Tricine SDS-PAGE and transferred to PVDF membranes, followed by blocking with 5% non-fat milk for 1 h at room temperature. The membranes were then incubated with primary antibodies targeting NF-κB p65 (1:1,000; cat. no. 4764; Cell Signaling Technology, Inc.), phosphorylated (p-) p65 (1:1,000; cat. no. 3033; Cell Signaling Technology, Inc.) and GAPDH (1:5,000; cat. no. ab9485; Abcam) overnight at 4°C. The next day, after washing, the membranes were incubated with HRP-conjugated goat anti-rabbit polyclonal IgG secondary antibodies (1:2,000; ab6721; Abcam) for overnight at 4°C. The next day, after washing, the membranes were incubated with primary antibodies targeting NF-κB p65 (1:100; cat. no. 4764; Cell Signaling Technology, Inc.), phosphorylated (p-) p65 (1:100; cat. no. 3033; Cell Signaling Technology, Inc.) and GAPDH (1:5,000; cat. no. ab9485; Abcam) overnight. The membranes were then incubated with HRP-conjugated goat anti-rabbit polyclonal IgG secondary antibodies (1:2,000; ab6721; Abcam) for half hour at room temperature. Immunoblotting was detected by chemiluminescent substrate and the experimental results were processed with ImageJ software (version 1.51j8, National Institutes of Health).

**Enzyme-linked immunosorbent assay (ELISA).** First, ice-cold PBS was used to homogenize DRG samples. Then, the bicinchoninic acid assay was used to determine the protein concentration in the samples. The levels of TNF-α and IL-6 were measured using commercially available rat-specific ELISA kits (IL-6 kit, cat. no. R60000B; TNF-α kit, cat. no. RTA00; R&D Systems, Inc.), following the manufacturer's instructions.

**Statistical analysis.** Data were presented as the mean ± standard error of the mean. Behavioral and western blotting results were analyzed by single factor or mixed factor designed ANOVA, followed by Dunnett's or simple-effects post hoc tests using SPSS software (version 21.0.0; IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Oxaliplatin-induced mechanical allodynia, cold alldynia and thermal hyperalgesia in rats.** First, the rat model of oxaliplatin-induced CIPNP was generated by injecting oxaliplatin (i.p., 2.5 mg/kg). Before oxaliplatin injection and 1, 2 and 3 weeks post-injection, von Frey hind-paw withdrawal thresholds, withdrawal response times for cold plate tests and hind-paw licking latencies for hot plate tests were assessed (Fig. 1A-C). Compared with vehicle-treated rats, oxaliplatin-treated rats displayed significant mechanical allodynia (Fig. 1A), cold alldynia (Fig. 1B) and thermal hyperalgesia (Fig. 1C) on the 7th day post-injection; these observations were sustained throughout the experiment. Additionally, the weight of the vehicle-treated rats increased during the experiment; although the oxaliplatin-treated rats also gained weight, the effect was less pronounced (Fig. 1D). Finally, motor function was significantly impaired in the oxaliplatin-treated rats compared with the vehicle-treated rats (Fig. 1E). These results indicated that treatment with oxaliplatin resulted in mechanical allodynia, cold alldynia and thermal hyperalgesia. In addition, the impaired weight gain and motor function suggested that the oxaliplatin-induced CIPNP model was successfully established in the present study.

**Effects of a single injection of berberine on oxaliplatin-induced alldynia.** On the 21st day following the first injection of oxaliplatin, a single injection of 5, 10 or 20 mg/kg berberine was administered to the rats to examine the effect of berberine as a treatment on pre-established CIPNP. A previous report (25) reported these relief effects at 60 min after the berberine injection. Fig. 2A demonstrates that, according to a von Frey test, the hind-paw withdrawal thresholds of oxaliplatin-treated rats decreased compared with the vehicle-treated rats. The acetone drop tests showed increased withdrawal response times (Fig. 2B) and the hot plate tests showed decreased hind-paw-licking latency (Fig. 2C) compared with the vehicle-treated rats. However, a single injection of berberine significantly reduced mechanical allodynia (Fig. 2A), cold allodynia (Fig. 2B) and thermal hyperalgesia (Fig. 2C). Although the dose of 5 mg/kg of berberine could effectively relieve cold hyperalgesia and thermal hyperalgesia, it did not have a significant effect on mechanical hyperalgesia; therefore, the doses of 10 and 20 mg/kg of berberine were used for the following experiments.

**Effects of repeated doses of berberine on oxaliplatin-induced mechanical allodynia, cold allodynia and thermal hyperalgesia.** As shown in Fig. 3, when the rats were repeatedly injected with berberine throughout the CIPNP induction experiment, berberine reversed CIPNP establishment, depending on the dose. The oxaliplatin and berberine-treated rats displayed only partial development of mechanical allodynia and cold allodynia compared with the oxaliplatin-treated rats on all test days (Fig. 3A and B). In hot plate tests, the oxaliplatin and berberine-treated rats displayed a distinct increase in hind paw licking latency compared with the oxaliplatin-treated rats (Fig. 3C). Weight gain measurements produced results similar to those for oxaliplatin-treated rats, with the oxaliplatin and berberine-treated rats not gaining as much weight as the vehicle-treated rats (Fig. 3D). However, motor function in the oxaliplatin and berberine-treated rats was significantly ameliorated compared with the oxaliplatin-treated rats, and similar to the levels of the control vehicle-treated rats (Fig. 3E). These results revealed that berberine dose-dependently prevented the development of CIPNP in rats without affecting motor function.

**Effects of repeated injections of berberine on oxaliplatin-induced NF-κB phosphorylation.** A recent study revealed that the NF-κB signaling pathway is associated with
chemotherapy-induced chronic pain (13). In addition, activation of NF-κB in DRGs has been demonstrated to mediate chronic pain caused by inflammatory reactions (14). To understand the mechanism underlying the analgesic effect of berberine, the protein expression levels of NF-κB p65 and the phosphorylated NF-κB p65 were examined in DRGs from the rats administered with oxaliplatin and either saline control or the 20 mg/kg dose of berberine. The western blotting results demonstrated that oxaliplatin treatment significantly induced NF-κB p65 phosphorylation (Fig. 4A and B), while repeated injections of berberine suppressed oxaliplatin-induced NF-κB p65 phosphorylation (Fig. 4A and B). These findings indicated that the analgesic effect of berberine might occur through the regulation of NF-κB phosphorylation in DRGs.

Effects of repeated injections of berberine on IL-6 and TNF-α levels in rat DRGs. The ELISA method was used to detect the levels of IL-6 and TNF-α in rat DRGs. The results demonstrated that the levels of IL-6 and TNF-α significantly increased in the oxaliplatin-induced CIPNP model compared with the vehicle-treated rats (Fig. 5A and B). However, berberine administration significantly and dose-dependently suppressed these increases in IL-6 and TNF-α levels in the oxaliplatin-induced CIPNP model (Fig. 5A and B).
Discussion

As many as 80% of patients receiving cytostatic drugs are treated for CIPNP (26). As the number of cancer survivors increases, treating this upsetting side effect has become a top priority. Although several drugs for preventing or treating CIPNP have been considered in experimental research, few have been applied effectively in clinical practice (27). The present study found that repeated doses of berberine during oxaliplatin treatment significantly prevented the severity of CIPNP in rats. This effect was associated with the suppressed phosphorylation of NF-κB p65, and with decreased levels of the cytokines IL-6 and TNF-α, in DRGs. The present results indicate that berberine might have an analgesic role in oxaliplatin-induced CIPNP by preventing NF-κB p65 phosphorylation and pro-inflammatory cytokine release in DRGs.

Berberine has been reported to relieve allodynia and to display antioxidant effects in models of diabetic neuropathy (23) and peripheral nerve injury (24). The present study included behavioral observations to demonstrate that oxaliplatin injection in rats could induce mechanical allodynia, cold allodynia and thermal hyperalgesia. Of note, a single dose of berberine significantly reduced oxaliplatin-induced pain behaviors in the pre-established CIPNP process, while repeated administration acted as a preventative treatment to the development and establishment of oxaliplatin-induced CIPNP. However, berberine did not produce pain behaviors in naive animals (28). The present results suggest that berberine can potentially prevent and treat neuropathic pain, including
One of the limitations of the present study was the use of only male animals in the behavioral tests. Further analysis with both male and female animals will be necessary to confirm these conclusions.

Berberine’s analgesic mechanism in oxaliplatin-induced CIPNP has not been extensively studied. The main mechanisms of oxaliplatin-induced peripheral neuropathy include ion-channel imbalance, neuronal inflammation, neuronal damage and oxidative stress (26). Accumulating evidence indicates that NF-κB activation and pro-inflammatory cytokines mediate chemotherapy-induced neuropathy and that NF-κB activation is also involved in pathological pain caused by nerve damage or inflammation (11,12). The most well-known functional heterodimer of NF-κB in cells is the p50/p65 complex (29). Given NF-κB p65 requires phosphorylation before binding to specific target genes in the nucleus, NF-κB activation can be demonstrated by an increase in p-p65 expression (30). It has also been reported that berberine...
prevents the extracellular matrix degradation and apoptosis of human nucleus pulposus cells by inhibiting the NF-κB pathway (31). The present study demonstrated that repeated administration of berberine during the induction of CIPNP significantly inhibited the NF-κB activation in DRGs induced by oxaliplatin. Combined with previous studies, the present results indicate that NF-κB might participate in the mechanism responsible for the analgesic effect of berberine in DRGs.

Previous studies have hypothesized that the spinal cord may be involved in the effect of berberine in CIPNP. For example, it has been reported that berberine reduces spinal cord neuroglia activation in streptozotocin-induced diabetic mice (28). Protein expression levels of inducible nitric oxide synthase and cyclooxygenase-2 in DRG and spinal cord have also been shown to be suppressed by berberine in the context of diabetic neuropathic pain. Levels of IL-6, IL1β and TNF-α, in either the DRG or the spinal cord, have also been shown to be reduced by berberine. These results indicate that the mechanism underlying the effect of berberine might be similar in the DRG and the spinal cord; however, this requires further exploration.

It is known that chemotherapeutic agents, such as paclitaxel, vincristine and oxaliplatin, can induce painful peripheral neuropathy by inducing pro-inflammatory cytokines (32,33). Activation of NF-κB is a critical signaling pathway in the chronic pain context, mediating inflammatory reactions and altering ion channel expression (34). Additionally, NF-κB is a pleiotropic regulator that regulates the expression of many different genes.
including genes that transcribe pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β (35). This explains the increased levels of IL-6 and TNF-α in the DRG of rats following oxaliplatin injection observed in the present study. The present study demonstrated that NF-κB p65 phosphorylation and expression of the pro-inflammatory cytokines IL-6 and TNF-α were substantially increased in the DRG of animals with oxaliplatin-induced CIPNP. Furthermore, the present study revealed that these increases were significantly suppressed by berberine, suggesting that berberine might relieve CIPNP through inhibiting NF-κB phosphorylation and the release of pro-inflammatory cytokines. Nonetheless, other mechanisms of berberine that might be involved with CIPNP cannot be excluded.

In conclusion, the present study demonstrated an analgesic effect of berberine both as a treatment on pre-established oxaliplatin-induced CIPNP and as a preventative during the establishment of oxaliplatin-induced CIPNP, by decreasing NF-κB p65 phosphorylation and pro-inflammatory cytokine IL-6 and TNF-α release in DRGs. The present results indicate that berberine may have an analgesic effect on CIPNP, thus further research confirming its effectiveness in a clinical setting is warranted.

Acknowledgements
Not applicable.

Funding
The present work was supported by grants from the Natural Science Foundation of Hubei province (grant no. 2018C cxB920).

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions
QX and WN were responsible for the concept and design of the study. WN, XZ, LH and CK performed experiments and data analysis. QX and WN performed data interpretation, presentation and writing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All experimental procedures were performed in compliance with the Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of Huazhong University of Science and Technology (Wuhan, China).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

References


